Cisbani Giulia, Maxan Alexander, Kordower Jeffrey H, Planel Emmanuel, Freeman Thomas B, Cicchetti Francesca
Centre de Recherche du CHU de Québec-Université Laval, Axe Neurosciences, 2705 Boulevard Laurier, Québec, QC, Canada.
Department of Neurological Sciences and Center for Brain Repair, Rush University Medical Center, Chicago, IL 60612, USA.
Brain. 2017 Nov 1;140(11):2982-2992. doi: 10.1093/brain/awx255.
Cell replacement has been explored as a therapeutic strategy to repair the brain in patients with Huntington's and Parkinson's disease. Post-mortem evaluations of healthy grafted tissue in such cases have revealed the development of Huntington- or Parkinson-like pathology including mutant huntingtin aggregates and Lewy bodies. An outstanding question remains if tau pathology can also be seen in patients with Huntington's and Parkinson's disease who had received foetal neural allografts. This was addressed by immunohistochemical/immunofluorescent stainings performed on grafted tissue of two Huntington's disease patients, who came to autopsy 9 and 12 years post-transplantation, and two patients with Parkinson's disease who came to autopsy 18 months and 16 years post-transplantation. We show that grafts also contain tau pathology in both types of transplanted patients. In two patients with Huntington's disease, the grafted tissue showed the presence of hyperphosphorylated tau [both AT8 (phospho-tau Ser202 and Thr205) and CP13 (pSer202) immunohistochemical stainings] pathological inclusions, neurofibrillary tangles and neuropil threads. In patients with Parkinson's disease, the grafted tissue was characterized by hyperphosphorylated tau (AT8; immunofluorescent staining) pathological inclusions, neurofibrillary tangles and neuropil threads but only in the patient who came to autopsy 16 years post-transplantation. Abundant tau-related pathology was observed in the cortex and striatum of all cases studied. While the striatum of the grafted Huntington's disease patient revealed an equal amount of 3-repeat and 4-repeat isoforms of tau, the grafted tissue showed elevated 4-repeat isoforms by western blot. This suggests that transplants may have acquired tau pathology from the host brain, although another possibility is that this was due to acceleration of ageing. This finding not only adds to the recent reports that tau pathology is a feature of these neurodegenerative diseases, but also that tau pathology can manifest in healthy neural tissue transplanted into the brains of patients with two distinct neurodegenerative disorders.
细胞替代疗法已被探索作为修复亨廷顿舞蹈症和帕金森病患者大脑的一种治疗策略。对此类病例中健康移植组织的尸检评估显示,出现了类似亨廷顿舞蹈症或帕金森病的病理变化,包括突变型亨廷顿蛋白聚集体和路易小体。一个悬而未决的问题是,在接受胎儿神经异体移植的亨廷顿舞蹈症和帕金森病患者中,是否也能观察到tau蛋白病理变化。通过对两名亨廷顿舞蹈症患者(分别在移植后9年和12年进行尸检)以及两名帕金森病患者(分别在移植后18个月和16年进行尸检)的移植组织进行免疫组织化学/免疫荧光染色,解决了这一问题。我们发现,在这两类移植患者的移植物中均存在tau蛋白病理变化。在两名亨廷顿舞蹈症患者中,移植组织显示存在高磷酸化tau蛋白(AT8(磷酸化tau蛋白Ser202和Thr205)和CP13(pSer202)免疫组织化学染色)病理包涵体、神经原纤维缠结和神经毡丝。在帕金森病患者中,移植组织的特征是高磷酸化tau蛋白(AT8;免疫荧光染色)病理包涵体、神经原纤维缠结和神经毡丝,但仅在移植后16年进行尸检的患者中出现。在所有研究病例的皮质和纹状体中均观察到大量与tau蛋白相关的病理变化。虽然移植的亨廷顿舞蹈症患者的纹状体显示tau蛋白的3重复和4重复异构体数量相等,但通过蛋白质印迹法显示移植组织中4重复异构体升高。这表明移植物可能从宿主大脑中获得了tau蛋白病理变化,尽管另一种可能性是这是由于衰老加速所致。这一发现不仅补充了最近关于tau蛋白病理变化是这些神经退行性疾病特征的报道,而且还表明tau蛋白病理变化可在移植到患有两种不同神经退行性疾病患者大脑中的健康神经组织中表现出来。